Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-75
SponsorPeking Union Medical College Hospital

About this trial

This single-center, retrospective, observational study aims to construct a standardized benchmark evaluation system for intelligent breast ultrasound image interpretation and to systematically assess the diagnostic performance of current mainstream multimodal artificial intelligence (AI) models.

De-identified B-mode breast ultrasound images with confirmed pathological diagnoses will be retrospectively collected from the institutional archive (2018-2025) and supplemented with images from published open-access datasets. Expert radiologists with varying experience levels will independently annotate all images according to the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) v2025 criteria, including glandular tissue composition, lesion characterization (mass vs. non-mass lesion), morphological descriptors, and final BI-RADS classification.

Baseline deep learning models (CNN-based ResNet-50 and Transformer-based USFM) will be trained to establish performance baselines and to stratify cases by diagnostic difficulty through cross-architecture consensus. Multiple multimodal large language models (MLLMs), including both general-purpose and medical-domain models, will then be evaluated via standardized API calls using BI-RADS-guided chain-of-thought prompts at temperature 0 for reproducibility.

Primary endpoints include BI-RADS classification accuracy and diagnostic AUC for benign-malignant differentiation. Model robustness and safety will be assessed through out-of-distribution rejection testing, temperature-stability experiments, and thinking-mode ablation studies. This study adheres to the FLAIR and TRIPOD-LLM reporting guidelines.

Eligibility criteria

Qualifiers

B-mode breast ultrasound grayscale images from the institutional PACS database or from published open-access breast ultrasound datasets with documented original institutional ethics approval

Image quality adequate for clinical diagnosis with clear visualization of the region of interest

Pathological diagnosis confirmed (for benign and malignant lesion groups), or normal breast status confirmed by a senior radiologist with >15 years of breast ultrasound experience (for the normal group)

Complete de-identification with removal of all personally identifiable information

Disqualifiers

Severely degraded image quality precluding meaningful BI-RADS assessment

Duplicate images from the same patient (only the most representative image retained per lesion)

Images with residual personally identifiable information after de-identification processing

Cases with ambiguous, disputed, or unavailable pathological results

Trial design

Treatments tested in this trial

  • Multimodal AI Model Diagnostic Evaluation

Treatment groups

1,380 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Peking Union Medical College Hospital

Lead sponsor

Chinese Academy of Medical Sciences

Collaborator